1. Home
  2. CUK vs BIIB Comparison

CUK vs BIIB Comparison

Compare CUK & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carnival Plc ADS ADS

CUK

Carnival Plc ADS ADS

HOLD

Current Price

$31.82

Market Cap

34.2B

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$174.80

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CUK
BIIB
Founded
1972
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.2B
24.2B
IPO Year
2000
1991

Fundamental Metrics

Financial Performance
Metric
CUK
BIIB
Price
$31.82
$174.80
Analyst Decision
Strong Buy
Buy
Analyst Count
18
22
Target Price
$35.06
$177.40
AVG Volume (30 Days)
2.4M
2.7M
Earning Date
12-19-2025
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
40.51
N/A
EPS
2.02
10.97
Revenue
$26,622,000,000.00
$10,065,900,000.00
Revenue This Year
$6.91
$3.61
Revenue Next Year
$3.94
N/A
P/E Ratio
$14.79
$15.93
Revenue Growth
6.40
4.77
52 Week Low
$13.65
$110.04
52 Week High
$31.24
$185.17

Technical Indicators

Market Signals
Indicator
CUK
BIIB
Relative Strength Index (RSI) 81.10 54.75
Support Level $25.97 $168.56
Resistance Level $26.79 $175.94
Average True Range (ATR) 0.93 5.10
MACD 0.81 -1.52
Stochastic Oscillator 98.43 42.10

Price Performance

Historical Comparison
CUK
BIIB

About CUK Carnival Plc ADS ADS

Carnival is the largest global cruise company, with more than 90 ships in service. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America; P&O Cruises and Cunard Line in the United Kingdom; Aida in Germany; Costa Cruises in Southern Europe. It recently folded its P&O Australia brand into Carnival. The firm also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted 14 million guests in 2024.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: